Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer.

ABSTRACT:

Background

In prostate cancer (PCa), well-established biomarkers such as MSI status, TMB high, and PDL1 expression serve as reliable indicators for favorable responses to immunotherapy. Recent studies have suggested a potential association between CDK12 mutations and immunotherapy response; however, the precise mechanisms through which CDK12 mutation may influence immune response remain unclear. A plausible explanation for immune evasion in this subset of CDK12-mutated PCa may be reduced MHC expression.

Results

Using genomic data of CDK12-mutated PCa from 48 primary and 10 metastatic public domain samples and a retrospective cohort of 53 low-intermediate risk primary PCa, we investigated how variation in the expression of the MHC genes affected associated downstream pathways

SUBMITTER: Lautert-Dutra W 

PROVIDER: S-EPMC11070094 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature